QIAGEN PE Ratio 2010-2022 | QGEN

Current and historical p/e ratio for QIAGEN (QGEN) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. QIAGEN PE ratio as of December 01, 2022 is 19.20.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

QIAGEN PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-12-01 50.46 25.10
2022-09-30 41.28 $2.01 20.54
2022-06-30 47.20 $2.22 21.26
2022-03-31 49.00 $2.32 21.12
2021-12-31 55.58 $2.21 25.15
2021-09-30 51.68 $2.56 20.19
2021-06-30 48.38 $2.06 23.49
2021-03-31 48.69 $1.92 25.36
2020-12-31 52.85 $1.53 34.54
2020-09-30 52.26 $0.81 64.52
2020-06-30 42.81 $0.03 1427.00
2020-03-31 41.60 $-0.16 0.00
2019-12-31 33.80 $-0.20 0.00
2019-09-30 32.97 $-0.13 0.00
2019-06-30 40.55 $0.84 48.27
2019-03-31 40.68 $0.81 50.22
2018-12-31 34.45 $0.82 42.01
2018-09-30 37.88 $0.38 99.68
2018-06-30 36.16 $0.33 109.58
2018-03-31 32.31 $0.23 140.48
2017-12-31 30.93 $0.17 181.94
2017-09-30 31.50 $0.39 80.77
2017-06-30 33.53 $0.33 103.04
2017-03-31 28.97 $0.36 80.72
2016-12-31 29.10 $0.34 85.28
2016-09-30 28.50 $0.51 55.99
2016-06-30 22.65 $0.51 44.51
2016-03-31 23.20 $0.53 43.81
2015-12-31 28.71 $0.55 52.17
2015-09-30 26.81 $0.46 58.68
2015-06-30 25.74 $0.46 56.34
2015-03-31 26.17 $0.49 53.61
2014-12-31 24.36 $0.51 47.88
2014-09-30 23.65 $0.65 36.14
2014-06-30 25.39 $0.69 37.05
2014-03-31 21.90 $0.31 70.33
2013-12-31 24.73 $0.29 85.06
2013-09-30 22.22 $0.20 112.64
2013-06-30 20.68 $0.15 142.20
2013-03-31 21.89 $0.52 42.15
2012-12-31 18.85 $0.56 33.61
2012-09-30 19.22 $0.39 48.71
2012-06-30 17.34 $0.43 40.73
2012-03-31 16.17 $0.43 37.97
2011-12-31 14.34 $0.43 33.68
2011-09-30 14.36 $0.58 24.69
2011-06-30 19.75 $0.58 33.96
2011-03-31 20.82 $0.60 34.56
2010-12-31 20.30 $0.62 32.58
2010-09-30 18.42 $0.65 28.16
2010-06-30 19.96 $0.69 29.12
2010-03-31 23.87 $0.68 35.37
2009-12-31 23.19 $0.65 35.45
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.249B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.688B 10.41
GSK (GSK) United Kingdom $70.345B 8.82
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.600B 0.00
Arcus Biosciences (RCUS) United States $2.547B 38.23
Biohaven (BHVN) United States $1.078B 0.00
Emergent Biosolutions (EBS) United States $0.614B 4.82
Zymeworks (ZYME) Canada $0.486B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.281B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.074B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00